Evestra Prodrug 6-Month Injectable
EC625
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Evestra, Inc.
Details
- API: Not Yet Determined - Progestin
- Target: Progesterone Receptor
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: Not Yet Determined
- Regimen: 1 Injection/6 Months
- MPT: Not Potential MPT
- Promising Attributes: 6-month subcutaneous injectables may have improved side effect profiles and continuation when compared to existing injectables
Product Status
Preparing for IND & First-in-Human Trial
History
2022: Evestra announces product-specific funding from the Gates Foundation to support further development of a prodrug-based 6-month subcutaneous injectable. The announcement notes at least 5 years of Foundation support for contraceptive R&D